Dr. Brander has a long-standing interest in T cell immunity, having started his studies with mechanistic analyses on T cell hyperreactivity to antibiotics. He provides one of the first evidences that exogenous antigens can be taken up by antigen presenting cells and presented in the context of MHC class I to CD8 T cells. His lab focuses mostly on T cell responses to viral infections, including cancer-driving viruses and Hepatitis and Herpesviruses in the setting of HIV co-infection and in transplanted hosts. This work has also led to the design of HIV oriented immunogens, which are currently in clinical trial for therapeutic HIV vaccination. Dr. Brander is a curator of the Los Alamos National Laboratories HIV immunology database and co-founder of Aelix Therapeutics, a Barcelona-based, clinical stage biotech company who is developing HIV cure vaccine strategies.
« Go Back